Table 5 The interaction between gene promoter region methylation and different cancer stages for 5-year TTP of CRC patients.

From: Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan

 

Normal tissues

Tumor tissues

No. of subjects

No. of cases (%)

Crude

Adjusted

No. of subjects

No. of cases (%)

Crude

Adjusted

HR

95% CI

HR

95% CI

  

HR

95% CI

HR

95% CI

≧2 of genes

UnMe/local (1&2)

36

6 (16.7)

1.00

Referent

1.00

Referent

20

4 (20.0)

1.00

Referent

1.00

Referent

UnMe/advanced (3&4)

31

16 (51.6)

3.49

(1.21 to 10.1)

6.30

(1.39 to 28.6)

8

3 (37.5)

2.50

(0.50 to 12.4)

7.36

(0.76 to 71.7)

Me/local (1&2)

41

3 (7.3)

0.19

(0.02 to 1.60)

0.32

(0.03 to 3.74)

57

5 (8.8)

0.34

(0.07 to 1.69)

0.51

(0.04 to 5.82)

Me/advanced (3&4)

45

38 (84.4)

9.76

(3.78 to 25.3)

15.0

(3.52 to 63.6)

68

51 (75.0)

6.47

(2.00 to 21.0)

11.5

(1.56 to 85.2)

p for trend

  

<0.01

 

<0.01

   

<0.01

 

<0.01

 
  1. Abbreviations: TTP, time to progression; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
  2. Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor ___location.
  3. UnMe/loccal (1&2): gene promoter region unmethylated with cancer stage 1 or 2.
  4. UnMe/advanced (3&4): gene promoter region unmethylated with cancer stage 3 or 4.
  5. Me/local (1&2): gene promoter region methylated with cancer stage 1 or 2.
  6. Me/advanced (3&4): gene promoter region methylated with cancer stage 3 or 4.
Back to article page